Albert Alexa E, Back Anthony L
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States.
Seattle Psychoanalytic Society and Institute, Seattle, WA, United States.
Front Psychiatry. 2025 Apr 2;16:1529427. doi: 10.3389/fpsyt.2025.1529427. eCollection 2025.
Pathological narcissism (PN) is a complex, treatment-resistant disorder characterized by unstable self-esteem that fluctuates between grandiosity and vulnerability, complicating the formation of a stable self-image. With few empirically supported therapies, treatment has traditionally relied on long-term psychoanalytic approaches, but these often face high attrition. Recent research suggests a potential therapeutic synergy between psychedelics and psychoanalytic therapy, offering a novel approach to addressing entrenched personality structures. Studies on MDMA (3,4-methylenedioxymethamphetamine), a compound known for enhancing empathy, trust, and social interactions, demonstrate potential to reopen critical periods for social learning in adults, offering the possibility of therapeutic benefits for conditions with core issues in relatedness, such as PN. MDMA promotes psychological flexibility and openness, allowing for deeper self-exploration and strengthening the observing ego, considered in psychoanalytic therapy to be an essential component for recognizing and modifying maladaptive patterns. By reducing fear-based avoidance in the brain, MDMA facilitates access to unconscious emotions, helping individuals process overwhelming feelings linked to early relational trauma commonly seen in PN. Additionally, MDMA's capacity to enhance compassion and empathy can fortify the therapeutic alliance, increasing its potential to facilitate relational change. This paper presents an MDMA-assisted therapy (MDMA-AT) tailored for narcissistic patients which is currently being conducted as an investigator-initiated trial (IIT). It explores the model's theoretical foundations, mechanisms of change, treatment framework, and clinical challenges. Combining MDMA with an evidence-based depth therapy like psychoanalytic psychotherapy may offer an innovative treatment for conditions associated with attachment and developmental trauma, particularly personality disorders. While the role of psychotherapy in psychedelic treatments remains a topic of debate, with some proposing psychedelics be administered without psychotherapy, we assert that individuals with early relational trauma stand the most to gain from an integrated psychedelic-assisted therapy (PAT) model, where MDMA enhances the therapeutic alliance and emotional openness while psychoanalytic interventions provide the structure for lasting change.
病理性自恋（PN）是一种复杂的、难治性疾病，其特征是自尊不稳定，在夸大与脆弱之间波动，这使得稳定自我形象的形成变得复杂。由于几乎没有得到实证支持的疗法，传统上治疗依赖于长期的精神分析方法，但这些方法往往面临高脱落率。最近的研究表明，迷幻剂与精神分析疗法之间可能存在治疗协同作用，为解决根深蒂固的人格结构提供了一种新方法。对3,4-亚甲基二氧甲基苯丙胺（MDMA）的研究表明，这种化合物以增强同理心、信任和社交互动而闻名，它有潜力重新开启成年人社交学习的关键期，为与关联性核心问题相关的疾病（如PN）带来治疗益处的可能性。MDMA促进心理灵活性和开放性，允许进行更深入的自我探索，并加强观察自我，在精神分析疗法中，观察自我被认为是识别和改变适应不良模式的重要组成部分。通过减少大脑中基于恐惧的回避，MDMA有助于接触无意识情绪，帮助个体处理与PN中常见的早期关系创伤相关的压倒性情绪。此外，MDMA增强同情心和同理心的能力可以加强治疗联盟，增加其促进关系改变的潜力。本文介绍了一种为自恋患者量身定制的MDMA辅助疗法（MDMA-AT），该疗法目前正在作为一项研究者发起的试验（IIT）进行。它探讨了该模型的理论基础、改变机制、治疗框架和临床挑战。将MDMA与循证深度疗法（如精神分析心理治疗）相结合，可能为与依恋和发育创伤相关的疾病，特别是人格障碍，提供一种创新治疗方法。虽然心理治疗在迷幻剂治疗中的作用仍然是一个有争议的话题，一些人提议在没有心理治疗的情况下使用迷幻剂，但我们断言，有早期关系创伤的个体最能从综合迷幻剂辅助疗法（PAT）模型中获益，在该模型中，MDMA增强治疗联盟和情感开放性，而精神分析干预为持久改变提供结构。
